A phase II study of HER3-DXD in patients (pts) with metastatic breast cancer (MBC)

被引：0
|
作者：
Hamilton, E. P. [1 ]
Bagegni, N. A. [2 ]
Beck, J. T. [3 ]
Cultrera, J. L. [4 ]
Dosunmu, O. [5 ]
Gwin, W. R. [6 ]
Heeke, A. L. [7 ]
Khoury, K. [8 ]
Sellami, D. [9 ]
Shastry, M. [10 ]
Sternberg, D. W. [11 ]
Toppmeyer, D. [12 ]
Wright-Browne, V. M. [13 ]
Yuan, Y. [14 ]
机构：
[1] Sarah Cannon Res Inst Canc Ctr, Drug Dev Unit, Nashville, TN USA
[2] Ctr Adv Med, Siteman Canc Ctr, St Louis, MO USA
[3] Highlands Oncol, Med Oncol, Springdale, AR USA
[4] Florida Canc Specialists North, Villages Canc Ctr, The Villages, FL USA
[5] Sarah Cannon Res Inst, Dev Innovat, Nashville, TN USA
[6] Canc Vaccine Inst Univ Washington, Med, Seattle, WA USA
[7] Levine Canc Inst Morehead, Breast & Surg Oncol, Charlotte, NC USA
[8] Univ Alabama Birmingham, Div Hematol & Oncol, ONeal Comprehens Canc Ctr 8, Birmingham, AL USA
[9] Daiichi Sankyo Inc, Oncol Dept, Basking Ridge, NJ USA
[10] Sarah Cannon Res Inst, Strateg Dev Dept, Nashville, TN USA
[11] Daiichi Sankyo Inc, Oncol R&D, Basking Ridge, NJ USA
[12] Rutgers Canc Inst New Jersey, Med Oncol, New Brunswick, NJ USA
[13] Florida Canc Specialists, Port Charlotte, FL USA
[14] City Hope Natl Med Ctr, Med Oncol & Therapeut Res, Duarte, CA USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.223
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
204TiP
引用
收藏
页码：S220 / S220
页数：1
相关论文
共 50 条
  • [41] Phase II study of sagopilone (ZK-Epo) in patients with recurrent metastatic breast cancer (MBC)
    Morrow, P. H.
    Divers, S. G.
    Provencher, L.
    Luoh, S.
    Petrella, T. M.
    Giurescu, M.
    Fielding, L.
    Wang, Y.
    Hortobagyi, G. N.
    Vahdat, L. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).
    Gil-Martin, Marta
    Pardo, Patricia Gomez
    Lopez-Tarruella, Sara
    Manso, Luis
    Perez-Fidalgo, Jose Alejandro
    Ademuyiwa, Foluso Olabisi
    Mayer, Ingrid A.
    Pluard, Timothy J.
    Garcia, Maria Martinez
    Kaufman, Peter A.
    Vandat, Linda T.
    Hooftman, Leon W.
    Romagnoli, Barbara
    Hernando, Cristina
    Weilbaecher, Katherine N.
    Ciruelos, Eva M.
    Martin, Miguel
    Simon, Sonia Pernas
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Mitoxantrone plus fluorouracil and leucovorin in the elderly patients with metastatic breast cancer (MBC): a phase II study
    La Grotta, G
    Brando, E
    Manzin, E
    Loddo, C
    Seles, E
    Bumma, C
    ANNALS OF ONCOLOGY, 1998, 9 : 76 - 76
  • [44] METRONOMIC ORAL VINORELBINE IN PATIENTS WITH METASTATIC BREAST CANCER (MBC): A PHASE II STUDY IN OUR INSTITUTION
    Nastasi, G.
    Cotroneo, G.
    Roda, G.
    Duluc, M.
    Castro, A.
    Maffioletti, L.
    Ravenda, P. S.
    ANNALS OF ONCOLOGY, 2009, 20
  • [45] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
    Cortes, J.
    Kim, S-B.
    Chung, W-P.
    Im, S-A.
    Park, Y. H.
    Hegg, R.
    Kim, M. H.
    Tseng, L-M.
    Petry, V.
    Chung, C-F.
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Verma, S.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1287 - S1288
  • [46] A phase II study of bi-weekly pegylated liposomal doxorubicin and paclitaxel in metastatic breast canecer (MBC) patients (pts)
    Ferrari, Vittori D.
    Simoncini, Edda
    Amoroso, Vito
    Grisanti, Salvatore
    Valcamonico, Francesca
    Vassalli, Lucia
    Marpicati, Patrizia
    Rangoni, Giovanni
    Marini, Giovanni
    ANNALS OF ONCOLOGY, 2004, 15 : 49 - 49
  • [47] Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC)
    Wang, R.
    Singh, J.
    Sterlin, V.
    Goldstein, M.
    Lake, D.
    Wong, S.
    Baselga, J.
    Norton, L.
    Dang, C.
    CANCER RESEARCH, 2019, 79 (04)
  • [48] Phase I clinical trial of bavituximab (Bavi) and paclitaxel (P) patients (pts) with HER2-negative metastatic breast cancer (MBC)
    Chalasani, Pavani
    Marron, Marilyn
    Clarke, Kathryn
    Schmidt, Kathy
    Powell, Alisa
    Iannone, Maria
    Stopeck, Alison
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Mitoxantrone and methotrexate (MM) in elderly patients (pts) with metastatic breast cancer (MBC)
    van Veelen, H
    Tjabbes, T
    Bong, SB
    Piersma, H
    Runhaar, EA
    Vermeer, RJ
    Scholtens, T
    ANNALS OF ONCOLOGY, 1998, 9 : 20 - 20
  • [50] Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC).
    Wang, Rui
    Singh, Jasmeet Chadha
    Wong, Serena Tsan-Lai
    Lake, Diana
    Iyengar, Neil M.
    D'Andrea, Gabriella
    Brockway-Marchello, Julia P.
    Kaba, Asta
    Traina, Tiffany A.
    Robson, Mark E.
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345